4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000040
Chief Medical Officer sold 4,055 shares at $28.96 ($117,433)
- Chief Medical Officer acquired 13,666 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Gheuens Sarah · Chief Medical Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-02 | Exercise or conversion : show line 1 in the form 10b5-1 | +4,000 | 68,795 | D | ||
| 2026-03-02 | Sale : show line 2 in the form 10b5-1 | −1,187 | $28.96 | $34,376 | 67,608 | D |
| 2026-03-02 | Exercise or conversion : show line 3 in the form 10b5-1 | +5,666 | 73,274 | D | ||
| 2026-03-02 | Sale : show line 4 in the form 10b5-1 | −1,681 | $28.96 | $48,682 | 71,593 | D |
| 2026-03-02 | Exercise or conversion : show line 5 in the form 10b5-1 | +4,000 | 75,593 | D | ||
| 2026-03-02 | Sale : show line 6 in the form 10b5-1 | −1,187 | $28.96 | $34,376 | 74,406 | D |
| Open-market sales · 4,055 sh · avg $28.96 · $117,433 | ||||||
Table II: Derivative
6 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-01 | Grant or award : show line 7 in the form 10b5-1 Restricted stock units | +14,000 | 14,000 | D |
| 2026-03-01 | Grant or award : show line 8 in the form 10b5-1 Restricted stock units | +22,000 | 22,000 | D |
| 2026-03-01 | Grant or award : show line 9 in the form 10b5-1 Stock options (right to buy) | +52,000 | 52,000 | D |
| 2026-03-02 | Exercise or conversion : show line 10 in the form 10b5-1 Restricted stock units | −4,000 | 0 | D |
| 2026-03-02 | Exercise or conversion : show line 11 in the form 10b5-1 Restricted stock units | −5,666 | 5,667 | D |
| 2026-03-02 | Exercise or conversion : show line 12 in the form 10b5-1 Restricted stock units | −4,000 | 8,000 | D |
Loading xslF345X05/wk-form4_1772572555.xml…